Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $19.77 USD
Change Today +0.46 / 2.38%
Volume 16.6K
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 9:51 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$19.26
Previous Close
$19.31
Day High
$19.79
Day Low
$19.18
52 Week High
07/20/15 - $21.65
52 Week Low
10/13/14 - $8.56
Market Cap
467.9M
Average Volume 10 Days
697.1K
EPS TTM
$-3.32
Shares Outstanding
23.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product includes Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. It markets and sells its products to physicians, nurses, and other healthcare professionals. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

70 Employees
Last Reported Date: 05/11/15
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $387.5K
Co-Founder and Director
Total Annual Compensation: $501.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $346.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $346.3K
Compensation as of Fiscal Year 2014.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. - Special Call

To discuss the overview of ZX008

Zogenix, Inc. Announces Executive Appointments

Zogenix, Inc. announced the appointments of Gail M. Farfel, Ph.D., as Executive Vice President and Chief Development Officer, and Thierry Darcis, M.D., M.B.A., as Executive Vice President and General Manager, Europe. In the Chief Development Officer role, Dr. Farfel will lead all product development activities, including clinical development and regulatory strategy. In his role, Dr. Darcis will establish company's pre-commercial presence in Europe and lead commercial operations in Europe for the anticipated launch of ZX008. Both Dr. Farfel and Dr. Darcis will report directly to Dr. Farr, Chief Executive Officer of the company. Dr. Farfel has over 20 years of experience in leading drug development projects for multiple CNS indications, including epilepsy. Most recently, she was Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, establishing and overseeing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. Previously, Dr. Farfel was Vice President, Therapeutic Area and Head for Neuroscience Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation, where she oversaw a portfolio of products including Gilenya® for multiple sclerosis, Exelon® and the Exelon® Patch for Alzheimer's disease and Parkinson's disease, and the antidepressant, agomelatine. Dr. Darcis has over 20 years of pharmaceutical industry experience in global marketing, product development and operations management. He has led European operations as General Manager for two successful rare disease-focused biopharmaceutical organizations, most recently NPS Pharmaceuticals and prior to that, Viropharma Europe. Previously, he was Vice President, Global Marketing Head and a member of the executive team at Novartis Vaccines. Prior to Novartis Vaccines, Dr. Darcis spent over five years with GlaxoSmithKline Biologicals in Belgium.

Zogenix, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:30 PM

Zogenix, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:30 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Stephen J. Farr, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $19.77 USD +0.46

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $8.09 USD -0.065
Corium International Inc $14.54 USD -0.12
Durect Corp $2.42 USD +0.07
Egalet Corp $11.48 USD -0.11
Elite Pharmaceuticals Inc $0.23 USD -0.002
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings 100.0x
Price/Sales 9.8x
Price/Book 10.8x
Price/Cash Flow 69.4x
TEV/Sales 11.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.